References
- 1Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci. 2010; 55: 560-578.2010146310.1007/s10620-009-1081-0LewisJRMohantySRNonalcoholic fatty liver disease: a review and updateDig Dis Sci201055560578
- 2Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001; 121:710-23.10.1053/gast.2001.2712611522755ReidAENonalcoholic steatohepatitisGastroenterology200112171023
- 3Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non alcoholic fatty liver disease. J Hepatol. 2004; 40: 578-84.15030972CaldwellSHCrespoDMThe spectrum expanded: cryptogenic cirrhosis and the natural history of non alcoholic fatty liver diseaseJ Hepatol20044057884
- 4Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37:917-23.1266898710.1053/jhep.2003.50161MarchesiniGBugianesiEForlaniGCerrelliFLenziMManiniRet alNonalcoholic fatty liver, steatohepatitis, and the metabolic syndromeHepatology20033791723
- 5Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142:1592-609.10.1053/j.gastro.2012.04.001ChalasaniNYounossiZLavineJEDiehlAMBruntEMCusiKet alThe diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of GastroenterologyGastroenterology20121421592609
- 6Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, Imai Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9:428-33.10.1016/j.cgh.2011.01.02321320639YasuiKHashimotoEKomorizonoYKoikeKAriiSImaiYet alCharacteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinomaClin Gastroenterol Hepatol2011942833
- 7Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313-21.10.1002/hep.2070115915461KleinerDEBruntEMVan NattaMBehlingCContosMJCummingsOWet alDesign and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatology200541131321
- 8Hjelkrem M, Stauch C, Shaw J, Harrison SA. Validation of the non-alcoholic fatty liver disease activity score. Aliment Pharmacol Ther. 2011; 34:214-8.10.1111/j.1365-2036.2011.04695.x21585409HjelkremMStauchCShawJHarrisonSAValidation of the non-alcoholic fatty liver disease activity scoreAliment Pharmacol Ther2011342148
- 9Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128:1898-1906.1594062510.1053/j.gastro.2005.03.084RatziuVCharlotteFHeurtierAGombertSGiralPBruckertEet alSampling variability of liver biopsy in nonalcoholic fatty liver diseaseGastroenterology200512818981906
- 10Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009; 49:1017-44.10.1002/hep.2274219243014RockeyDCCaldwellSHGoodmanZDNelsonRCSmithADLiver biopsyHepatology200949101744
- 11Musso G, Gambino R, Cassader M, Pagano G. Metaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Ann Med. 2011; 43: 617-49.10.3109/07853890.2010.518623MussoGGambinoRCassaderMPaganoGMetaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severityAnn Med20114361749
- 12Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012; 13: 239-50.10.1038/nrm331322436747RottiersVNaarAMMicroRNAs in metabolism and metabolic disordersNat Rev Mol Cell Biol20121323950
- 13Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology. 2012; 142:1431-43.10.1053/j.gastro.2012.04.00722504185WangXWHeegaardNHOrumHMicroRNAs in liver diseaseGastroenterology2012142143143
- 14Bala S, Marcos M, Szabo G. Emerging role of microRNAs in liver diseases. World J Gastroenterol. 2009; 15: 5633-40.10.3748/wjg.15.563319960558BalaSMarcosMSzaboGEmerging role of microRNAs in liver diseasesWorld J Gastroenterol200915563340
- 15Ceccarelli S, Panera N, Gnani D, Nobili V. Dual role of microRNAs in NAFLD. Int J Mol Sci. 2013; 14:8437-55.10.3390/ijms1404843723594995CeccarelliSPaneraNGnaniDNobiliVDual role of microRNAs in NAFLDInt J Mol Sci201314843755
- 16Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, et al. miR-34a/SIRT1/ p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013; 58: 119-25.2290255010.1016/j.jhep.2012.08.008CastroREFerreiraDMAfonsoMBBorralhoPMMachadoMVCortez-PintoHet almiR-34a/SIRT1/ p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver diseaseJ Hepatol20135811925
- 17Wong MY, Yu Y, Walsh WR, Yang JL. microRNA-34 family and treatment of cancers with mutant or wildtype p53 (Review). Int J Oncol. 2011; 38:1189-95.WongMYYuYWalshWRYangJLmicroRNA-34 family and treatment of cancers with mutant or wildtype p53 (Review)Int J Oncol201138118995
- 18Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012; 15:665-74.2256021910.1016/j.cmet.2012.04.004MinHKKapoorAFuchsMMirshahiFZhouHMaherJet alIncreased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver diseaseCell Metab20121566574
- 19Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013; 424:99-103.2372703010.1016/j.cca.2013.05.021YamadaHSuzukiKIchinoNAndoYSawadaAOsakabeKet alAssociations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liverClin Chim Acta201342499103
- 20Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011; 6:e23937.10.1371/journal.pone.002393721886843CermelliSRuggieriAMarreroJAIoannouGNBerettaLCirculating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver diseasePLoS One20116e23937
- 21Ortega FJ, Mercader JM, Catalan V, Moreno-Navarrete JM, Pueyo N, Sabater M, et al. Targeting the circulating microRNA signature of obesity. Clin Chem. 2013; 59: 781-92.10.1373/clinchem.2012.19577623396142OrtegaFJMercaderJMCatalanVMoreno-NavarreteJMPueyoNSabaterMet alTargeting the circulating microRNA signature of obesityClin Chem20135978192
- 22Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, et al. Systematic review with meta-analysis: noninvasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014; 39:254-69.10.1111/apt.12569KwokRTseYKWongGLHaYLeeAUNguMCet alSystematic review with meta-analysis: noninvasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragmentsAliment Pharmacol Ther20143925469
- 23Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006; 3:87-98.1645931010.1016/j.cmet.2006.01.005EsauCDavisSMurraySFYuXXPandeySKPearMet almiR-122 regulation of lipid metabolism revealed by in vivo antisense targetingCell Metab200638798
- 24Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008; 36: 1153-62.10.1093/nar/gkm111318158304ElmenJLindowMSilahtarogluABakMChristensenMLind-ThomsenAet alAntagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liverNucleic Acids Res200836115362
- 25Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, et al. Essential metabolic, anti-inflammatory, and antitumorigenic functions of miR-122 in liver. J Clin Invest. 2012; 122:2871-83.10.1172/JCI63539HsuSHWangBKotaJYuJCostineanSKutayHet alEssential metabolic, anti-inflammatory, and antitumorigenic functions of miR-122 in liverJ Clin Invest2012122287183
- 26Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012; 122:2884-97.10.1172/JCI63455TsaiWCHsuSDHsuCSLaiTCChenSJShenRet alMicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesisJ Clin Invest2012122288497